A Phase 2 interventional study of MM120 and Placebo in ADHD and Attention Deficit Disorder, sponsored by Definium Therapeutics US, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Definium Therapeutics US, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands — 4 open to participants now, 5 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Netherlands.
Among the 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands, this one is the 25th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 2, and was the 35th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →4 of the 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands are open now. Recruiting first, the newest first:
Universiteit Leiden · Sites in Netherlands
Ages 16–25
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Universiteit Leiden · Sites in Netherlands
Ages 4–13 · Healthy volunteers
Erasmus Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 12
First in 1999; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 107 across the 36 interventional studies, 90 across the 8 observational. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 44 have an industry lead sponsor. The 10 most frequent:
Definium Therapeutics US, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Definium Therapeutics US, Inc. has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Attention Deficit Disorder with Hyperactivity with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
This study is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of low dose MM120 (20 μg) compared with a placebo administered for 6 weeks (twice a week on a 3/4-day schedule).
Low dose MM120 (20 μg) is about 20% of the dose typically consumed for recreational psychedelic purposes.
There will be a 1:1 randomization, double-blind, to MM120 or placebo with the aim to reach 26 evaluable patients in each of the 2 arms at Week 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.
Other: Placebo
A total of 26 patients will receive 20 μg of MM120 administered orally twice weekly for 6 weeks.
Drug: MM120
MM120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM120 manifests primarily visual, as well as auditory, hallucinations.
Also known as: MM-120, DT120, lysergide tartrate
A treatment which is designed to have no therapeutic value.
Change in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms
The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.
Time frame: 6 weeks
Changes in Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Symptoms
The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.
Time frame: Week 2
Number of Patients Who Experience a Decrease in the Clinical Global Impressions Scale (CGI-S)
The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.
Time frame: Baseline, Week 2, Week 6, Week 10
Change From Baseline in in Clinical Global Impressions Scale (CGI-S)
The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.
Time frame: Baseline, Week 2, Week 6
Adult Attention-deficit/Hyperactivity Disorder Self-reporting Rating Scale (ASRS)
The Adult Attention-Deficit/Hyperactivity Disorder Self-Reporting Rating Scale (ASRS) is composed of 18 questions, and uses a scale that ranges from 0-4 based on the individuals mark in either the "never, rarely, sometimes, often, very often" column for a possible total score of 72. A higher score corresponds to a worse severity of ADHD.
Time frame: 6 weeks
Change From Baseline in Connors' Adult ADHD Rating Scale (CAARS)
The Connors' Adult ADHD Rating Scale (CAARS) Self-Report Long Form is a 66-item measure of ADHD symptom. Responses are scored on a 4-point scale, where 0 = not at all, 1 = just a little, 2 = pretty much, and 3 = very much. Item scores are summed to three main scores which are then transformed using population-derived age- and sex-adjusted norm values to a T-score. A T-score \< 60 indicates no ADHD. A T-score of 60-64 indicates borderline ADHD. A T-score of \> 64 indicates ADHD.
Time frame: 6 weeks
5 Dimensions of Altered States of Consciousness Questionnaire (5D-ASC) Scores
The 5 dimensions of altered states of consciousness (5D-ASC) scale is a visual analog scale (VAS) consisting of 94 items each scored on a 0-100mm VAS extrapolated to 100% scale for quantitative evaluation. These 94 items are categorized into five dimensions: oceanic boundlessness (min:0, max:2700), anxious ego dissolution (min:0, max:2100), visionary destructuralization (min:0, max:1800), auditory alterations (min:0, max:1600), and vigilance reduction (min:0, max:1200). The total score is the sum of all questions and can range from 0 to 9400. Higher scores = more alteration in state of consciousness.
Time frame: 6 weeks
Mystical Experience Questionnaire 30 Items (MEQ30)
The Mystical Experience Questionnaire 30 item (MEQ30) is a 30-item questionnaire rated on a six-point scale. The scale has been used to assess mystical experiences in studies using psilocybin and LSD. Higher scores = greater mystical experiences. The total score is expressed as a percentage of the maximum possible score (0 to 100%).
Time frame: 6 weeks
Summary of Drug Effects Visual Analog Scale (VAS)
A series of single item visual Analog Scales (VAS) are used repeatedly 0 -6 hours after drug administration: The following 9 items were used in VAS (0-100 mm): "any drug effect", "good drug effect", bad drug effect", "drug liking", "fear", nausea", "alteration of vision", "alteration of sense of time", and "the boundaries between myself and my surroundings seem to blur". VAS scores range from 0 = no effect to 100 = strong effect. The scores for each item are extrapolated to a 100% scale and presented for each time point of assessment.
Time frame: 6 hours
Pharmacokinetic Outcomes
Maximum Plasma Concentration \[Cmax\] of MM-120 in the blood at Week 1 Day 1
Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose
Pharmacokinetic Parameters (Cmax)
Maximum concentration (Cmax)
Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose
Pharmacokinetic Parameters (Tmax and t1/2)
Time to maximum concentration (Tmax), half life (t1/2)
Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose
Pharmacokinetic Parameters (AUC0-inf and AUC0-6h)
Area under the concentration curve from time 0 to infinity (AUC0-inf), Area under the concentration curve from time 0 to 6 hour (AUC0-6h)
Time frame: 0.5, 1, 2, 3, 4, 6 hours post-dose
| Milestone | Arm 2- MM120 | Arm 1- Placebo |
|---|---|---|
| Started | 27 | 26 |
| Completed | 23 | 23 |
| Not completed | 4 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Pregnancy | 0 | 1 |
The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.
| units on a scale | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Baseline | 37.4 ± 6.11 | 37.3 ± 5.24 |
| Week 6 | 29.6 ± 8.27 | 29.0 ± 8.47 |
The Adult ADHD investigator symptom rating scale (AISRS) total score consists of 18 items from the original Attention-deficit/hyperactivity Disorder Rating Scale (ADHD-RS). The ADHD-RS includes 9 items that address symptoms of inattention, and 9 items that address symptoms of impulsivity and hyperactivity. Each item is rated from 0 to 3. The AISRS total score can range from 0 to 54. A higher score corresponds to a worse severity of ADHD.
| units on a scale | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Baseline | 37.5 ± 5.76 | 36.9 ± 5.10 |
| Week 2 | 34.2 ± 6.49 | 32.1 ± 4.96 |
The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.
| Participants | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Baseline to Week 2 | 8 | 11 |
| Baseline to Week 6 | 16 | 15 |
| Baseline to Week 10 | 17 | 12 |
The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.
| units on a scale | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Baseline for Week 2 | 4.9 ± 0.71 | 4.7 ± 0.62 |
| Week 2 | 4.6 ± 0.70 | 4.3 ± 0.53 |
| Baseline for Week 6 | 4.9 ± 0.73 | 4.8 ± 0.60 |
| Week 6 | 4.0 ± 0.88 | 3.8 ± 0.85 |
The Adult Attention-Deficit/Hyperactivity Disorder Self-Reporting Rating Scale (ASRS) is composed of 18 questions, and uses a scale that ranges from 0-4 based on the individuals mark in either the "never, rarely, sometimes, often, very often" column for a possible total score of 72. A higher score corresponds to a worse severity of ADHD.
| units on a scale | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Baseline for Week 2 | 48.0 ± 7.01 | 43.9 ± 7.33 |
| Week 2 | 40.2 ± 9.26 | 36.7 ± 9.38 |
| Baseline for Week 4 | 48.6 ± 7.67 | 44.6 ± 7.61 |
| Week 4 | 35.2 ± 8.14 | 34.9 ± 9.29 |
| Baseline for Week 6 (Day 36) | 48.4 ± 7.10 | 44.2 ± 7.72 |
| Week 6 (Day 36) | 36.0 ± 9.99 | 33.1 ± 11.70 |
| Baseline to Week 6 (Day 40) | 49.6 ± 6.96 | 44.0 ± 7.86 |
| Week 6 (Day 40) | 31.0 ± 9.18 | 31.7 ± 12.0 |
The Connors' Adult ADHD Rating Scale (CAARS) Self-Report Long Form is a 66-item measure of ADHD symptom. Responses are scored on a 4-point scale, where 0 = not at all, 1 = just a little, 2 = pretty much, and 3 = very much. Item scores are summed to three main scores which are then transformed using population-derived age- and sex-adjusted norm values to a T-score. A T-score \< 60 indicates no ADHD. A T-score of 60-64 indicates borderline ADHD. A T-score of \> 64 indicates ADHD.
| units on a scale | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Change from baseline to Week 2 | -4.0 ± 5.79 | -2 ± 3.29 |
| Change from baseline to Week 4 | -6.9 ± 5.36 | -3.6 ± 4.4 |
| Change from Baseline to Week 6 (Day 36) | -5.6 ± 6 | -4.6 ± 5.1 |
| Change from Baseline to Week 6 (Day 40) | -6.3 ± 5.82 | -4.3 ± 5.98 |
The 5 dimensions of altered states of consciousness (5D-ASC) scale is a visual analog scale (VAS) consisting of 94 items each scored on a 0-100mm VAS extrapolated to 100% scale for quantitative evaluation. These 94 items are categorized into five dimensions: oceanic boundlessness (min:0, max:2700), anxious ego dissolution (min:0, max:2100), visionary destructuralization (min:0, max:1800), auditory alterations (min:0, max:1600), and vigilance reduction (min:0, max:1200). The total score is the sum of all questions and can range from 0 to 9400. Higher scores = more alteration in state of consciousness.
| units on a scale | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| W1D1 Oceanic boundlessness | 479.6 (277.3 to 681.9) | 161.3 (26.2 to 296.4) |
| W1D1 Anxious ego dissolution | 103.6 (35.5 to 171.6) | 19.0 (5.9 to 32.2) |
| W1D1 Visionary destructuralization | 233.4 (135.6 to 331.2) | 94.8 (18.6 to 171.0) |
| W1D1 Auditory alterations | 71.0 (12.2 to 129.7) | 32.7 (1.6 to 63.8) |
| W1D1 Vigilance reduction | 288.5 (198.0 to 379.0) | 155.2 (79.3 to 231.1) |
| W1D1 Total score | 1176.0 (781.4 to 1570.6) | 463.0 (166.9 to 759.1) |
| W6 Oceanic boundlessness | 403.3 (194.3 to 612.4) | 70.2 (16.0 to 124.4) |
| W6 Anxious ego dissolution | 41.0 (-0.6 to 82.7) | 4.2 (-0.4 to 8.7) |
| W6 Visionary destructuralization | 199.7 (86.9 to 312.5) | 32.9 (6.4 to 59.4) |
| W6 Auditory alterations | 18.4 (0.2 to 36.7) | 4.2 (0.0 to 8.4) |
| W6 Vigilance reduction | 90.3 (52.2 to 128.5) | 20.0 (6.9 to 33.1) |
| W6 Total scores | 752.9 (387.2 to 1118.6) | 131.4 (50.0 to 212.8) |
The Mystical Experience Questionnaire 30 item (MEQ30) is a 30-item questionnaire rated on a six-point scale. The scale has been used to assess mystical experiences in studies using psilocybin and LSD. Higher scores = greater mystical experiences. The total score is expressed as a percentage of the maximum possible score (0 to 100%).
| percentage of maximum possible score | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| Week 1 Day 1 | 22.37 (14.57 to 30.17) | 10.40 (3.97 to 16.84) |
| Week 6 | 20.50 (11.94 to 29.06) | 5.20 (1.40 to 9.01) |
A series of single item visual Analog Scales (VAS) are used repeatedly 0 -6 hours after drug administration: The following 9 items were used in VAS (0-100 mm): "any drug effect", "good drug effect", bad drug effect", "drug liking", "fear", nausea", "alteration of vision", "alteration of sense of time", and "the boundaries between myself and my surroundings seem to blur". VAS scores range from 0 = no effect to 100 = strong effect. The scores for each item are extrapolated to a 100% scale and presented for each time point of assessment.
| percentage of maximum possible score | Arm 2- MM-120 | Arm 1- Placebo |
|---|---|---|
| 0h Any drug effect | 0 (0 to 0) | 0 (0 to 0) |
| 0h Drug liking | 37.1 (0 to 55) | 44.9 (0 to 52) |
| 0h Fear | 2.7 (0 to 36) | 1.4 (0 to 23) |
| 0h Nausea | 1.1 (0 to 30) | 0 (0 to 0) |
| 0h Alteration of vision | 0 (0 to 0) | 0 (0 to 0) |
| 0h Alteration of sense of time | 0 (0 to 0) | 0 (0 to 0) |
| 0h Boundaries blur | 0 (0 to 0) | 0 (0 to 0) |
| 0.5h Any drug effect | 8.9 (0 to 78) | 11.3 (0 to 75) |
| 0.5h Drug liking | 44.4 (0 to 78) | 48.1 (0 to 83) |
| 0.5h Fear | 2.0 (0 to 54) | 2.2 (0 to 48) |
| 0.5h Nausea | 2.0 (0 to 53) | 0.2 (0 to 3) |
| 0.5h Alteration of vision | 3.5 (0 to 54) | 7.4 (0 to 81) |
| 0.5h Alteration of sense of time | 2.5 (0 to 41) | 3.2 (0 to 35) |
| 0.5h Boundaries blur | 3.0 (0 to 71) | 0.8 (0 to 12) |
| 1h Any drug effect | 24.1 (0 to 100) | 12.7 (0 to 64) |
| 1h Drug liking | 49.7 (0 to 97) | 51.8 (2 to 97) |
| 1h Fear | 1.4 (0 to 32) | 0.1 (0 to 2) |
| 1h Nausea | 2.7 (0 to 37) | 1.0 (0 to 23) |
| 1h Alteration of vision | 4.0 (0 to 56) | 6.9 (0 to 72) |
| 1h Alteration of sense of time | 8.1 (0 to 73) | 6.3 (0 to 68) |
| 1h Boundaries blur | 6.0 (0 to 87) | 1.5 (0 to 24) |
| 2h Any drug effect | 38.1 (0 to 97) | 12.8 (0 to 72) |
| 2h Drug liking | 57.3 (0 to 100) | 53.3 (3 to 100) |
| 2h Fear | 4.1 (0 to 68) | 0.1 (0 to 2) |
| 2h Nausea | 8.2 (0 to 60) | 0.1 (0 to 2) |
| 2h Alteration of vision | 13.0 (0 to 84) | 6.2 (0 to 88) |
| 2h Alteration of sense of time | 13.5 (0 to 78) | 4.4 (0 to 53) |
| 2h Boundaries blur | 12.3 (0 to 83) | 1.3 (0 to 14) |
| 3h Any drug effect | 44.3 (0 to 97) | 11.1 (0 to 65) |
| 3h Drug liking | 61.6 (0 to 100) | 53.1 (3 to 96) |
| 3h Fear | 2.9 (0 to 54) | 0.2 (0 to 2) |
| 3h Nausea | 8.0 (0 to 56) | 0.2 (0 to 3) |
| 3h Alteration of vision | 13.9 (0 to 84) | 6.5 (0 to 76) |
| 3h Alteration of sense of time | 12.3 (0 to 89) | 4.9 (0 to 74) |
| 3h Boundaries blur | 12.7 (0 to 88) | 1.4 (0 to 31) |
| 4h Any drug effect | 38.5 (0 to 97) | 15.1 (0 to 100) |
| 4h Drug liking | 60.7 (0 to 100) | 48.0 (2 to 100) |
| 4h Fear | 2.7 (0 to 50) | 0.1 (0 to 2) |
| 4h Nausea | 6.9 (0 to 65) | 0.1 (0 to 2) |
| 4h Alteration of vision | 12.4 (0 to 86) | 3.2 (0 to 37) |
| 4h Alteration of sense of time | 12.1 (0 to 92) | 7.0 (0 to 57) |
| 4h Boundaries blur | 6.9 (0 to 69) | 0.2 (0 to 2) |
| 6h Any drug effect | 16.7 (0 to 75) | 9.6 (0 to 72) |
| 6h Drug liking | 54.8 (0 to 100) | 49.6 (0 to 100) |
| 6h Fear | 2.3 (0 to 52) | 2.1 (0 to 48) |
| 6h Nausea | 3.6 (0 to 52) | 0.2 (0 to 4) |
| 6h Alteration of vision | 4.1 (0 to 59) | 5.8 (0 to 59) |
| 6h Alteration of sense of time | 6.3 (0 to 69) | 3.0 (0 to 55) |
| 6h Boundaries blur | 4.1 (0 to 61) | 0.1 (0 to 2) |
Maximum Plasma Concentration \[Cmax\] of MM-120 in the blood at Week 1 Day 1
| ng/mL | Arm 2- MM-120 |
|---|---|
| Pre-dose (0 hours) | 0 ± 0 |
| 0.5hours | 0.3250 ± 0.16534 |
| 1hour | 0.4410 ± 0.15686 |
| 2hours | 0.4270 ± 0.12832 |
| 3hours | 0.3591 ± 0.12493 |
| 4hours | 0.3066 ± 0.10851 |
| 6hours | 0.2117 ± 0.09361 |
Maximum concentration (Cmax)
| ng/mL | Arm 2- MM-120 |
|---|---|
| Pharmacokinetic Parameters (Cmax) | 0.4811 ± 0.14279 |
Time to maximum concentration (Tmax), half life (t1/2)
| hours | Arm 2- MM-120 |
|---|---|
| Tmax | 1.46 ± 0.706 |
| t1/2 | 3.8187 ± 1.27269 |
Area under the concentration curve from time 0 to infinity (AUC0-inf), Area under the concentration curve from time 0 to 6 hour (AUC0-6h)
| ng*h/mL | Arm 2- MM-120 |
|---|---|
| AUC0-inf | 3.2450 ± 1.58494 |
| AUC0-6hr | 1.9411 ± 0.63490 |
Collected over From time of signing ICF (or screening visit) through study completion, typically 14 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 2- MM120 | 0/27 (0%) | 0/27 (0%) | 21/27 (77.8%) |
| Arm 1- Placebo | 0/26 (0%) | 0/26 (0%) | 23/26 (88.5%) |
| Event | Arm 2- MM120 | Arm 1- Placebo |
|---|---|---|
| HeadacheNervous system disorders | 13/27 | 9/26 |
| NasopharyngitisInfections and infestations | 3/27 | 5/26 |
| NauseaGastrointestinal disorders | 5/27 | 1/26 |
| IllusionPsychiatric disorders | 4/27 | 0/26 |
| FatigueGeneral disorders | 4/27 | 1/26 |
| InsomniaPsychiatric disorders | 3/27 | 1/26 |
| Disturbance in AttentionNervous system disorders | 2/27 | 2/26 |
| ApathyPsychiatric disorders | 1/27 | 2/26 |
| Abdominal painGastrointestinal disorders | 1/27 | 2/26 |
| FlatulenceGastrointestinal disorders | 2/27 | 0/26 |
A summary of demographic information for the FAS is shown below.
| Age, Continuous(years) | Arm 2- MM120 | Arm 1- Placebo | Total |
|---|---|---|---|
| Mean | 40.3 ± 12.8 | 33.1 ± 11.0 | 36.7 ± 12.4 |
| Sex: Female, Male(Participants) | Arm 2- MM120 | Arm 1- Placebo | Total |
|---|---|---|---|
| Female | 13 | 9 | 22 |
| Male | 14 | 17 | 31 |
| Race (NIH/OMB)(Participants) | Arm 2- MM120 | Arm 1- Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 27 | 26 | 53 |
| Region of Enrollment(participants) | Arm 2- MM120 | Arm 1- Placebo | Total |
|---|---|---|---|
| Netherlands | 2 | 1 | 3 |
| Switzerland | 25 | 25 | 50 |
| Baseline ADHD investigator symptom rating scale (AISRS)(units on a scale) | Arm 2- MM120 | Arm 1- Placebo | Total |
|---|---|---|---|
| Mean | 37.4 ± 6.11 | 37.3 ± 5.24 | 37.4 ± 5.69 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Nov 2023, 22 months.
Results were first posted in Apr 2025, 1 year 5 months after primary completion.
Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 22 months is above that.
Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lysergide D-tartrate
Attention Deficit Disorder with Hyperactivity →
Definium Therapeutics US, Inc.